Acute Lymphobkastic Leukemia Recruiting Phase 4 Trials for Cytarabine (DB00987)

IndicationStatusPhase
DBCOND0068117 (Acute Lymphobkastic Leukemia)Recruiting4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02036489Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic LeukemiaTreatment